NAP in Combination With Docetaxel Following Obinutuzumab Pretreatment in Subjects With Checkpoint Inhibitor Pretreated Advanced or Metastatic NSCLC
Clinical trial NCT04880863 · COMPLETED
Trial details
- NCT number
- NCT04880863
- Sponsor
- NeoTX Therapeutics Ltd.
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2021-10-26
- Primary completion
- 2024-01-30
- Enrollment
- 38
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.